Full-Time

Global Safety Officer

I&I

Updated on 9/3/2026

Deadline 9/11/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$178.5k - $297.5k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

Hybrid

Hybrid work is indicated.

MD

Category
Biology & Biotech
Required Skills
Data Science
Risk Management
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • Provide pharmacovigilance and risk management expertise to internal and external customers.
  • Serve as the safety expert for assigned products.
  • Maintain knowledge of the product, product environment, recent literature, pharmacovigilance expertise, and international safety regulations and guidelines.
  • Communicate and represent the pharmacovigilance position within project and product teams, with external partners, key opinion leaders, and health authorities, and during internal and external negotiations.
  • Provide strategic and proactive safety input into development plans.
  • Support due diligence activities and pharmacovigilance agreements.
  • Conduct ongoing assessment of product safety status.
  • Review, prepare, contribute to, and approve clinical development documents, including clinical development plans, statistical analysis plans, study protocols, investigator brochures, data monitoring plans, study reports, integrated summaries of safety, summaries of clinical safety, and labeling.
  • Review and contribute to questions from health authorities, ethics committees, institutional review boards, and external partners.
  • Manage product safety alerts.
  • Ensure the global pharmacovigilance and epidemiology position is clearly communicated to internal and external customers.
  • Establish credibility for the global safety officer function and global pharmacovigilance and epidemiology organization.
  • Demonstrate excellent clinical judgment.
  • Synthesize and critically analyze data from multiple sources.
  • Communicate complex clinical issues and analyses orally and in writing.
  • Develop and document sound risk assessments.
  • Demonstrate initiative and the capacity to work under pressure.
  • Demonstrate leadership within a cross-functional team environment.
  • Demonstrate teamwork and interpersonal skills.
  • Be fluent in written and spoken English.
  • Hold an M.D. degree or equivalent.
  • Have a minimum of three years of total experience in international pharmacovigilance or equivalent relevant industry experience, such as clinical development, with relevant clinical experience considered.
Responsibilities
  • Lead cross-functional Safety Management Teams and Global Pharmacovigilance and Epidemiology internal Safety Analysis Teams.
  • Identify and implement proactive safety analysis strategies to further define the safety profile.
  • Lead aggregate safety data review activities and coordinate safety surveillance activities.
  • Provide proactive risk assessments.
  • Co-lead benefit-risk assessments with relevant functions.
  • Develop risk management strategies and plans and monitor their effectiveness.
  • Represent the safety position in cross-functional submission teams.
  • Ensure the generation, consistency, and quality of safety sections in submission documents.
  • Write responses to or contributions for health authority questions.
  • Support the preparation and conduct of Advisory Committee meetings.
  • Document, coordinate, review, and validate periodic reports, including Risk Management Plan updates, Investigational New Drug annual reports, Annual Safety Reports or Development Safety Update Reports, and Periodic Safety Update Reports.
  • Serve as the medical safety expert to the Global Pharmacovigilance and Epidemiology Periodic Reports group for assigned projects and products.
Desired Qualifications
  • Board certified or board eligible for an M.D., or equivalent.
  • Proven excellence in a similar prior position may compensate for less than three years of international pharmacovigilance experience.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.